Journal
THERAPEUTIC ADVANCES IN DRUG SAFETY
Volume 3, Issue 2, Pages 59-69Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2042098611430109
Keywords
bevacizumab; efficacy; pharmacodynamics; safety
Categories
Ask authors/readers for more resources
With the 1997 filing of an investigational new drug application for the first agent to target angiogenesis, bevacizumab entered into phase I clinical trials and has now become a mainstay in the treatment of several cancers. Bevacizumab has changed the treatment approach for cancers due to its efficacy as well as toxicity. This article serves as a review of current efficacy data including recently published safety analyses and the direction of future pharmacodynamic evaluation to hopefully better guide its utilization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available